On October 11, 2022 Mission Therapeutics ("Mission"), a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes (DUBs), reported that Dr Paul Wallace, Chief Business Officer, and Dr Suhail Nurbhai, Chief Medical Officer, will attend the 14th Annual Parkinson’s Disease Conference on 13 October 2022 in New York (Press release, Mission Therapeutics, OCT 11, 2022, View Source [SID1234621887]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Parkinson’s Disease Therapeutics Conference is the only conference globally that focuses exclusively on Parkinson’s disease drug development, providing an unmatched platform for industry leaders to share exciting new and unpublished data from the field. Mission will join over 300 research and business professionals in attending poster and speaker presentations.